Name: 글로벌 시장 동향
SKU: PH2586
Availability: InStock

보고서 요약(국문)

세계 확장성 심근병증 치료제 시장 개요
세계 확장성 심근병증 치료제 시장 규모는 2022년 4억 490만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023-2030년) 동안 연평균 성장률(CAGR)은 5.90%입니다.
확장성 심근병증(DCM)은 심장 근육의 이상으로, 일반적으로 심장의 주요 펌프 역할을 하는 좌심실에서 시작됩니다. 좌심실이 약해지고 확장되어 혈액을 제대로 펌프질하지 못하게 됩니다. 심부전의 흔한 원인 중 하나는 심장이 신체에 충분한 혈액을 공급하지 못하는 것이며, 확장성 심근병증은 부정맥, 혈전, 또는 급사에도 영향을 미칠 수 있습니다. 확장성 심근병증(DCM)은 유아와 어린이를 포함한 모든 연령대의 사람들에게 영향을 미치지만, 20~50세 남성에게서 가장 흔하게 발생합니다.
세계 확장성 심근병증 치료제 시장 - 시장 동향
세계 확장성 심근병증 치료제 시장은 심장 질환 유병률 증가, 심근 감염 환자 수 증가, 약물 또는 알코올 남용 등의 요인에 의해 성장하고 있습니다.
심장 질환 유병률 증가는 예측 기간 동안 세계 확장성 심근병증 치료제 시장 성장을 견인할 것으로 예상됩니다.
확장성 심근병증은 매년 전체 울혈성 심부전 환자의 30~40%를 차지합니다. 확장성 심근병증의 유병률은 2,500명당 1명으로 추정됩니다. 이 질환은 심부전의 가장 흔한 원인 중 하나입니다. 확장성 심근병증의 부검을 통한 발병률은 연간 인구 10만 명당 4.5건으로 추정되는 반면, 임상 발병률은 연간 인구 10만 명당 2.45건입니다. 울혈성 심장 질환의 발병률 증가로 효과적인 약물과 치료법에 대한 필요성이 시급해지면서 확장성 심근병증 치료제 시장이 성장하고 있습니다.
세계보건기구(WHO)의 2020년 통계에 따르면 허혈성 심장 질환은 전 세계 사망 원인의 16%를 차지합니다. 2020년 2월에 발표된 "프랑스의 심부전(HF): 만성 심부전 치료 관리 및 실제 환경에서의 심장 기능 부전 위험"이라는 제목의 기사에 따르면 프랑스에서는 약 100만 명이 심부전으로 고통받고 있습니다. 잘 정립된 치료 관리에도 불구하고 심부전 관련 사망자는 약 7만 명에 달하고 입원 환자는 15만 명이 넘습니다.

확장성 심근병증 치료에 대한 수요가 증가함에 따라 여러 주요 제약 회사들이 확장성 심근병증 치료제 개발을 위한 임상 시험을 시작했습니다. 확장성 심근병증에 대해 FDA 승인을 받은 특정 약물이 없기 때문에, 치료는 울혈성 심부전과 동일하게 진행됩니다.
확장성 심근병증 치료를 위해 개발 중인 몇 가지 약물은 다음과 같습니다.
ARRY-371797(ARRY-797이라고도 함)은 Array Biopharma 연구진이 발견한 경구용 p38 미토겐 활성화 단백질 키나제(MAPK) 억제제입니다. 라민 A/C 유전자 변이로 인한 확장성 심근병증 환자 치료를 위한 3상 임상 시험이 진행 중입니다. 2019년 화이자는 파이프라인 확장을 위해 Array Biopharma를 인수했습니다. 이 약물은 화이자에서 PF-07265803이라는 이름으로 확장성 심근병증 환자 치료를 위한 3상 임상 시험 단계에 있습니다.

2020년 2월, 게이오 대학 연구팀은 유도만능줄기세포(iPS 세포)에서 유래한 심근 세포를 중증 심부전 환자에게 이식하는 연구에 대한 승인을 받았습니다. 이 연구는 2020년 말까지 진행될 예정이며, 심근 세포의 수축 기능이 저하된 확장성 심근병증 환자를 대상으로 합니다.
확장성 심근병증 치료제의 부작용이 시장 성장을 저해하고 있습니다.
그러나 확장성 심근병증 치료제의 부작용은 환자에게 심각한 불편함을 초래하여 시장 성장을 저해하고 있습니다. 또한, 이식형 기기 및 유망한 유전자 치료법의 등장으로 시장 성장에 걸림돌이 되고 있습니다.

세계 확장성 심근병증 치료제 시장 - 산업 분석
세계 확장성 심근병증 치료제 시장은 포터의 5가지 경쟁력 분석, 파이프라인 분석, 규제 분석, 역학, 미충족 수요 등 다양한 산업 요인을 기반으로 심층적인 시장 분석을 제공합니다.
세계 확장성 심근병증 치료제 시장 - 세그먼트 분석
약물 종류별 세그먼트는 예측 기간(2023-2030년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
약물 종류별로 확장성 심근병증 치료제 시장은 안지오텐신 전환 효소(ACE) 억제제, 베타 차단제, 알도스테론 길항제, 안지오텐신 II 수용체 차단제 및 기타로 세분화됩니다. 안지오텐신 II 수용체 차단제 약물 종류는 특히 선진국에서 확장성 심근병증 치료에 사용되는 블록버스터급 약물에 대한 수요 증가로 인해 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

반면, 알도스테론 길항제는 ARB 또는 ACE 억제제와 병용 투여 시 뒤센 근디스트로피(DMD) 진행을 늦추는 데 긍정적인 효과가 있는 것으로 확인되어 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 이러한 적응증에 대한 승인은 알도스테론 길항제의 전체 매출을 더욱 가속화하여 시장 성장에 긍정적인 영향을 미칠 것입니다. 일부 연구에 따르면 발사르탄과 같은 안지오텐신 수용체 차단제는 입원 확률을 28%까지 줄일 수 있습니다. 또한 이러한 약물은 수축기 심장 질환 환자의 사망률을 37% 감소시키고 입원 빈도를 줄이는 데 효과적입니다. 일반적인 항부정맥제로는 아미오다론, 프로카이나마이드, 리도카인이 있습니다. 코를라노르는 심장 동방결절의 자발적인 박동 활동을 감소시키는 과분극 활성화 고리형 뉴클레오티드 게이트 채널 차단제입니다. 미국 FDA는 6개월에서 18세 사이의 소아 확장성 심근병증 환자의 안정형 증상성 심부전(HF) 치료를 위해 코를라노르(이바브라딘)를 승인했습니다. 이 승인은 증상성 확장성 심근병증(DCM)을 앓고 있는 6개월에서 18세 미만의 소아 환자 116명을 대상으로 한 무작위 이중맹검 위약 대조 시험을 기반으로 합니다. 이 환자들은 정상 동률, NYHA/Ross 분류 II~IV 등급의 심부전, 좌심실 박출률 ≤45%였습니다. 연구의 1차 평가변수는 초기 용량 조절 기간 후 서맥이나 증상 없이 안정 시 심박수가 기준치 대비 20% 이상 감소하는 것이었습니다.
글로벌 확장성 심근병증 치료제 시장 – 지역별 분석
북미 지역은 전 세계 확장성 심근병증 치료제 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
심혈관 질환 발병률 증가, 잘 구축된 보험 제도, 그리고 선진 의료 인프라가 주요 요인입니다. 미국에서 2020년 심부전(HF) 치료 비용(직접 및 간접 비용 포함)은 총 436억 달러로 추산되며, 이 중 70% 이상이 의료비입니다. 미국은 고령 인구 증가와 심장 질환 발병률 상승으로 인해 이 지역에서 가장 큰 시장 점유율을 차지하고 있으며, 이는 해당 지역의 수요 증가로 이어지고 있습니다. 따라서 심혈관 질환 발병률이 증가함에 따라 확장성 심근병증 시장 또한 성장하고 있습니다.
또한, 시장 참여 기업들은 확장성 심근병증 치료를 위한 신약 개발에 연구 투자를 확대하고 있습니다. 예를 들어, 인공지능을 활용한 신약 개발 기업인 리커전 파마슈티컬스(Recursion Pharmaceuticals)는 2019년 7월 베일리 기포드(Baillie Gifford)가 주도한 투자 라운드에서 1억 2,100만 달러를 유치했습니다. 이 회사는 2018년 투자 유치에 성공한 신약 개발 스타트업으로, 투자자들은 컴퓨터 비전과 머신러닝과 같은 기술을 통해 비용이 많이 들고 복잡한 신약 개발 과정이 혁신될 것이라는 기대감으로 이 분야에 몰려들고 있습니다. 리커션(Recursion)은 희귀 질환 치료제 자체 개발을 추진하고 있으며, 다케다(Takeda) 및 사노피(Sanofi)와 같은 주요 제약 회사와 다른 희귀 질환 분야에서 파트너십을 맺고, 종양학 및 염증과 같은 분야에서 제약 회사와의 계약 체결을 희망하고 있습니다.
출처: DataM Intelligence 분석(2019)
글로벌 확장성 심근병증 치료제 시장 경쟁 구도
글로벌 확장성 심근병증 치료제 시장은 젠선 상하이 과학기술(Zensun Shanghai Sci & Tech Co Ltd), 카프리코 테라퓨틱스(Capricor Therapeutics, Inc), 아스트라제네카(AstraZeneca plc.), 베리셀(Vericel Corporation), 화이자(Pfizer Inc.), t2cure GmbH, 마이오카디아(MyoKardia), 카시아크 리서치(Kasiak Research Pvt. Ltd.) 등 여러 주요 업체들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 업체들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 채택하여 글로벌 확장성 심근병증 치료제 시장의 성장에 기여하고 있습니다. 예를 들어, 2019년 10월 노바티스는 1세 이상 소아 환자의 전신성 좌심실 수축 기능 장애를 동반한 증상성 심부전(HF) 치료를 위해 엔트레스토(사쿠비트릴/발사르탄)에 대한 미국 식품의약국(FDA) 승인을 받았습니다. 엔트레스토는 NT-proBNP 수치를 감소시키며 심혈관 질환 예후 개선에 도움이 될 것으로 기대됩니다.
글로벌 확장성 심근병증 치료제 시장 – 주목해야 할 주요 기업
화이자
개요: 화이자는 종양학, 염증, 심혈관 질환 및 기타 치료 분야에 의약품, 백신, 의료기기 및 소비자 건강 관리 제품을 제공하는 미국의 다국적 제약 회사입니다. 화이자는 15개 치료 분야에 걸쳐 150개 이상의 제품 포트폴리오를 보유하고 있습니다. 이 회사는 면역학, 종양학, 심장학, 내분비학 및 신경학을 포함한 광범위한 의학 분야의 의약품과 백신을 개발 및 생산합니다.

제품 포트폴리오: 캄지오스는 심근병증 환자를 위한 최초의 새로운 치료 옵션입니다.
주요 개발 사항: 2022년 8월 18일, 화이자는 확장성 심근병증 치료제 엠프루마피모드의 개발을 중단했습니다.
글로벌 확장성 심근병증 치료제 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 180페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Global Dilated Cardiomyopathy Therapeutics Market - Overview
The global dilated cardiomyopathy therapeutics market size was valued at US$ 404.9 million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 5.90% during the forecast period (2023-2030).
Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contributes to irregular heartbeats (arrhythmias), blood clots, or sudden death. People of all ages are affected by DCM, including infants and children, but it is most common in men ages 20 to 50.
Global Dilated Cardiomyopathy Therapeutics Market- Market Dynamics
The global dilated cardiomyopathy therapeutics market growth driven by certain factors such by rising prevalence of heart problems, the increasing number of people suffering from cardiac muscle infections, and drug or alcohol abuse.
Rising prevalence of heart problems, is expected to drive the global dilated cardiomyopathy therapeutics market during the forecast period
Dilated cardiomyopathy accounts for 30-40% of the total number of congestive heart failures each year. The estimated prevalence of dilated cardiomyopathy is 1:2500. This condition is one of the most common causes of heart failure. The incidence of dilated cardiomyopathy discovered at autopsy is estimated to be 4.5 cases per 100,000 population per year, whereas the clinical incidence is 2.45 cases per 100,000 population per year. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.
According to statistics from the World Health Organization (WHO) for 2020, ischemic heart disease is to blame for 16% of all fatalities worldwide. According to a February 2020 article titled "Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting," approximately one million people in France would be affected by HF. Despite well-defined treatment management, there are nearly 70,000 HF-related deaths and more than 150,000 hospitalizations.
With the rising demand for dilated cardiomyopathy treatment, several major companies have initiated to carry out clinical trials to develop drugs for dilated cardiomyopathy. There is no specific FDA-approved drug for dilated cardiomyopathy because of which the treatment administered is the same as that for congestive heart failure.
Some of the emerging drugs for the treatment of dilated cardiomyopathy are:
ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial to treat patients suffering from dilated cardiomyopathy because of a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for the treatment of patients affected by dilated cardiomyopathy.
In February 2020, a Keio University research team was given the green light to transplant heart muscle cells derived from iPS cells into patients who have experienced severe heart failure. The study aims to conduct study by the end of 2020 and targets patients with dilated cardiomyopathy, which lowers the systolic function of heart muscle cells.
Side effects associated with dilated cardiomyopathy therapeutics hampering the growth of the market
However, the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market. Moreover, the availability of implantable devices and promising gene therapy are acting as roadblocks to the market.
Global Dilated Cardiomyopathy Therapeutics Market- Industry Analysis
The global dilated cardiomyopathy therapeutics market provides in-depth analysis of the market based on various industry factors such as porter’s five force analysis, pipeline analysis, regulatory analysis, regulatory analysis, epidemiology, unmet needs etc.
Global Dilated Cardiomyopathy Therapeutics Market - Segment Analysis
The drug class segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
Based on drug class, the dilated cardiomyopathy therapeutics market is segmented by drug class into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers, and others. The angiotensin II receptor blockers drug class is estimated to account for the largest market share, owing to the rising demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions.
On the other hand, the aldosterone antagonists are expected to grow at the highest CAGR over the forecast period due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. According to some studies, the angiotensin receptor blockers such as valsartan can reduce the probability of hospitalization by 28%. These drugs are also effective for patients with systolic heart disease by reducing deaths by 37% and reducing hospitalization frequency. Common anti-arrhythmia medications include amiodarone, procainamide, and lidocaine. Corlanor is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the cardiac sinus node's spontaneous pacemaker activity. The US FDA approval of Corlanor (ivabradine) for the treatment of stable symptomatic heart failure (HF) due to dilated cardiomyopathy in pediatric patients aged 6 months to 18 years was based on a randomized, double-blind, placebo-controlled trial in 116 patients aged 6 months to less than 18 years with symptomatic DCM in sinus rhythm, NYHA/Ross class II to IV HF, and left ventricular ejection fraction ≤45%. The study's primary endpoint was ≥ a 20% reduction in resting heart rate from baseline without bradycardia or symptoms after an initial titration period.
Global Dilated Cardiomyopathy Therapeutics Market –Geographical Analysis
North America region holds the largest market share of the global dilated cardiomyopathy therapeutics market
The rising incidence of cardiovascular diseases, well-established insurance policies, and the availability of advanced healthcare infrastructure are the major factors. In the USA, the total cost of care (direct and indirect costs) for HF in 2020 is estimated at $43.6 billion, with over 70% of costs attributed to medical costs. In this region, the United States holds the largest market share due to rising geriatric populations, an increasing number of heart diseases in the country, which boosts the demand in this region. Hence, as the number of cardiovascular diseases increases, the market for dilated cardiomyopathy also increases.
Besides, the market players are investing in research and development to conduct new treatment drugs for dilated cardiomyopathy. For instance, in July 2019, Recursion Pharmaceuticals, which uses artificial intelligence to discover drugs, has raised $121 million in a round led by Baillie Gifford. The company is a new drug discovery start-up to raise funds in 2018, as investors flock to the sector hoping that the costly and cumbersome process of finding a drug will be transformed by techniques such as computer vision and machine learning. Recursion is trying to make its own drugs for rare diseases and partner with major pharmaceutical companies such as Takeda and Sanofi on other rare diseases, and hoping to sign deals with pharma companies in areas such as oncology and inflammation.
Source: DataM Intelligence Analysis (2019)
Global Dilated Cardiomyopathy Therapeutics Market Competitive Landscape
The global dilated cardiomyopathy therapeutics market is moderately competitive with several major players, including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer Inc., t2cure GmbH, MyoKardia, Kasiak Research Pvt. Ltd., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the dilated cardiomyopathy therapeutics market globally. For instance, in October 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. Entresto reduces NT-proBNP and is expected to improve cardiovascular outcomes.
Global Dilated Cardiomyopathy Therapeutics Market – Key Companies to Watch
Pfizer Inc
Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.
Product Portfolio: Camzyos is the first novel therapy option available for cardiomyopathy patients.
Key Developments: In August, 18th 2022, Pfizer discontinued the development of dilated cardiomyopathy drug emprumapimod.
The global dilated cardiomyopathy therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Drug class
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising prevalence of heart diseases
4.2.2. Increasing drugs and alcohol abuse
4.3. Restraints:
4.3.1. Side-effects of dilated cardiomyopathy drugs
4.4. Opportunity
4.5. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
6. By Drug class
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment.
6.3. Market Attractiveness Index, By Drug Class Segment
6.3.1. Angiotensin-converting enzyme (ACE) Inhibitors*
6.3.1.1. Introduction
6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.3.2. Beta-blockers
6.3.3. Aldosterone antagonists
6.3.4. Angiotensin II Receptor Blockers
6.3.5. Others
7. By Distribution Channel
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
7.3. Market Attractiveness Index, By Distribution Channel Segment
7.3.1. Hospitals & Clinics*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Online Channels
7.3.3. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. The U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. The U.K.
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. Australia
8.5.5.5. Rest of Asia Pacific
8.6. The Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. AstraZeneca plc*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Zensun Shanghai Sci & Tech Co Ltd
10.3. Pfizer Inc.
10.4. Capricor Therapeutics, Inc.
10.5. MyoKardia
10.6. Kasiak Research Pvt. Ltd.
10.7. Array BioPharma
10.8. Vericel Corporation
10.9. t2cure GmbH (*List is not exhaustive)
11. DataM Intelligence
11.1. Appendix
11.2. About Us and Services
11.3. Contact Us

언급된 주요 기업들

AstraZeneca plc, Zensun Shanghai Sci & Tech Co Ltd, Pfizer Inc., Capricor Therapeutics, Inc., MyoKardia, Kasiak Research Pvt. Ltd., Array BioPharma, Vericel Corporation

표 목록 (Tables)

List of Tables

Table 1 Global Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)

Table 2 Global Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)

Table 3 Global Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Million)

Table 4 Global Dilated Cardiomyopathy Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 5 Global Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)

Table 6 Global Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 7 Global Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)

Table 8 Global Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 9 Global Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Million)

Table 10 Global Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 11 Global Dilated Cardiomyopathy Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 12 Global Dilated Cardiomyopathy Therapeutics Market Value, By Region, 2022-2033 (US$ Million)

Table 13 North America Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 14 North America Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 15 North America Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 16 North America Dilated Cardiomyopathy Therapeutics Market Value, By Country, 2022-2033 (US$ Million)

Table 17 Europe Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 18 Europe Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 19 Europe Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 20 Europe Dilated Cardiomyopathy Therapeutics Market Value, By Country, 2022-2033 (US$ Million)

Table 21 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 22 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 23 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 24 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Value, By Country, 2022-2033 (US$ Million)

Table 25 South America Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 26 South America Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 27 South America Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 28 South America Dilated Cardiomyopathy Therapeutics Market Value, By Country, 2022-2033 (US$ Million)

Table 29 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 30 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 31 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 32 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Value, By Country, 2022-2033 (US$ Million)

Table 33 Bristol-Myers Squibb Company: Overview

Table 34 Bristol-Myers Squibb Company: Product Portfolio

Table 35 Bristol-Myers Squibb Company: Key Developments

Table 36 Constant Therapeutics LLC: Overview

Table 37 Constant Therapeutics LLC: Product Portfolio

Table 38 Constant Therapeutics LLC: Key Developments

Table 39 Cumberland Pharmaceuticals: Overview

Table 40 Cumberland Pharmaceuticals: Product Portfolio

Table 41 Cumberland Pharmaceuticals: Key Developments

Table 42 Novartis AG: Overview

Table 43 Novartis AG: Product Portfolio

Table 44 Novartis AG: Key Developments

Table 45 AstraZeneca: Overview

Table 46 AstraZeneca: Product Portfolio

Table 47 AstraZeneca: Key Developments

Table 48 Merck & Co., Inc.: Overview

Table 49 Merck & Co., Inc.: Product Portfolio

Table 50 Merck & Co., Inc.: Key Developments

Table 51 Rocket Pharmaceuticals: Overview

Table 52 Rocket Pharmaceuticals: Product Portfolio

Table 53 Rocket Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 2 Global Dilated Cardiomyopathy Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 3 Global Dilated Cardiomyopathy Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Dilated Cardiomyopathy Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Dilated Cardiomyopathy Therapeutics Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Dilated Cardiomyopathy Therapeutics Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 7 Angiotensin Receptor/Neprilysin Inhibitors (ARNI) Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 8 Aldosterone Antagonists Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 9 Antiarrhythmics Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 10 ACE Inhibitors Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 11 Beta-Blockers Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 12 Anticoagulants Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 13 Diuretics Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 14 Others Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 15 Global Dilated Cardiomyopathy Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 16 Oral Route of Administration in Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 17 Parenteral Route of Administration in Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 18 Others Route of Administration in Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 19 Global Dilated Cardiomyopathy Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 20 Hospital Pharmacies Distribution Channel in Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 21 Online Pharmacies Distribution Channel in Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 23 Global Dilated Cardiomyopathy Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 24 North America Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 25 North America Dilated Cardiomyopathy Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 26 North America Dilated Cardiomyopathy Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 27 North America Dilated Cardiomyopathy Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 28 North America Dilated Cardiomyopathy Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 29 Europe Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 30 Europe Dilated Cardiomyopathy Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 31 Europe Dilated Cardiomyopathy Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 32 Europe Dilated Cardiomyopathy Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 33 Europe Dilated Cardiomyopathy Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 34 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 35 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 36 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 37 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 38 Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 39 South America Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 40 South America Dilated Cardiomyopathy Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 41 South America Dilated Cardiomyopathy Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 42 South America Dilated Cardiomyopathy Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 43 South America Dilated Cardiomyopathy Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 44 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Value, 2022-2033 (US$ Million)

Figure 45 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)

Figure 46 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 47 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 48 Bristol-Myers Squibb Company: Financials

Figure 49 Constant Therapeutics LLC: Financials

Figure 50 Cumberland Pharmaceuticals: Financials

Figure 51 Novartis AG: Financials

Figure 52 AstraZeneca: Financials

Figure 53 Merck & Co., Inc.: Financials

Figure 54 Rocket Pharmaceuticals: Financials